Bipolar Disorder Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2030
Overview
The Global Bipolar Disorder Market Size was valued at USD 5.5 Billion in 2023 and the total Global Bipolar Disorder revenue is expected to grow at a CAGR of 3.4 % from 2024 to 2030, reaching nearly USD 6.95 Billion by 2030
Global Bipolar Disorder Market Overview
Bipolar disorders (BD) are a group of severe lifelong disorders that are associated with staggering loss of human capital, loss of healthy living years as well as lifespan. Although mania is the defining feature of Global Bipolar Disorder I disorder, and hypomania with at least one depressive episode defines Global Bipolar Disorder II disorder, it is well-established that depressive symptoms and episodes are the predominant illness presentation. The predominance of depressive symptoms across Global Bipolar Disorder subtypes is apparent not only at the first illness presentation but also along the longitudinal course.
To know about the Research Methodology :- Request Free Sample Report
Surged in the prevalence of mental health disorders has propelled the market growth in 2023. The Global Bipolar Disorder market is expected to grow during the forecast period owing to increased stress among adults, lifestyle changes, increased high demand for anti-depressants, and advances in the combination drug therapeutic market that have boosted the Bipolar Disorder market growth. Bipolar disorder is a complex and difficult disorder to treat as awareness of available treatments and specific benefits and hazards, along with early and accurate diagnosis, facilitate better outcomes for those suffering from extremely distressing and disabling chronic illnesses. Lithium remains the most useful drug for acute treatment and prevention in Global Bipolar Disorder treatment. With the changing perspective on mental health, the demand for natural Global Bipolar Disorder meds or drugs is anticipated to grow among patients suffering from such diseases.
1. According to MMR analysis, approximately 34% of individuals with Bipolar disorder attempt suicide and 15% to 20% of people with Bipolar disorder die by suicide.
2.Sumitomo Dainippon Pharma, along with its subsidiary Sunovion Pharmaceuticals, is one of the leading players in the Bipolar disorder market and is expected to remain during the forecast period.
Global Bipolar Disorder Market Dynamics
Increased Awareness, Government Initiatives, and Medical Advancements in Global Bipolar Disorder Market
Increasing public awareness of the disease and providing affordable, accessible diagnosis assistance has surged the market growth. Global Bipolar Disorder Market awareness also aims to eliminate several stereotypes related to Bipolar Disorder, which weaken people's self-confidence in asking for help and has been accelerating the market growth. The increase in the government's initiatives to develop an educated society is increasing the number of people seeking outpatient treatment has boosted the growth of the market. Scientific successes or medical research have extended the field of medicine to include new aspects of diseases, defining them in several categories. The growing capabilities of medicine to cover all aspects of diseases are leading to an increase in diagnoses, which is driving the global market for Bipolar disorder.
Challenges in Global Bipolar Disorder Diagnosis and Treatment
The complex nature of Bipolar disorder and its overlapping symptoms with other mental illnesses make it challenging to diagnose accurately. Misdiagnosis or delayed diagnosis hinders effective treatment and management of the disease. A lack of awareness among the public and health professionals about Bipolar disorder has resulted in underdiagnoses and under treatment. Long-term treatment and medication are frequently necessary for individuals with Bipolar disorder. The Bipolar Disorder medication side effects, stigma, lack of social support, and various symptoms hinder treatment adherence. The increase in the risk of recurrence and worsening of the disease is heightened by inadequate treatment adherence. Disparities in access to mental health services, including limited access to mental health professionals, inadequate insurance coverage, and financial constraints, created significant challenges for people with Bipolar disorder to receive timely and appropriate help as a result it hindered the market growth.
Global Bipolar Disorder Market Segment Analysis
Based on Treatment Type, the Mood stabilizers Segment holds the highest market share at 54.00 % with a growing CAGR of 4.78% during the forecast period. Mood stabilizers are a class of medications used in the management and treatment of Bipolar disorder. Bipolar disorder or manic-depression is a severe and common psychiatric illness that is often treated with mood-stabilizing drugs. In 2023, there has been a significant surge in the use of mood stabilizers, primarily as psychiatric drugs for treating mood disorders like Bipolar disorder. The market has grown significantly owing to various factors such as the increasing prevalence of mental illness, the increasing geriatric population, and increasing awareness and acceptance of mental health treatments. The pharmaceutical industry is striving to create new formulations that exhibit superior effectiveness, side effects, and long-lasting characteristics. In addition, precision medicine and personalized therapies hold promising opportunities for tailoring mood stabilizers to specific patient needs. Mood stabilizers, such as Carbamazepine, Lamotrigine, Valproate, and Asenapine, which are used to cure Bipolar disorder resulting in propelled in the market growth.
Global Bipolar Disorder Market Regional Insights
North America dominated the Global Bipolar Disorder Market with the highest market share accounting for 53.80% in 2023, the region is expected to grow during the forecast period and maintain its dominance by 2030. The market is fuelled by the increasing prevalence of mood disorders and the growing demand for effective treatment options. Major factors that are driving the growth of the Bipolar disorder treatment market include increased awareness of the condition, improved healthcare system, and higher rates of onset of symptoms associated with high levels of stress and poor lifestyle. The increasing prevalence of ADHD in the region has increased the demand for ADHD therapists. With its advanced healthcare infrastructure and high healthcare spending, the United States has a significant market share in the global market. The US market makes up the majority of total global sales, contributing to more than 80% owing to the large Bipolar disorder population, combined with the high price of medication in the country.
1. 7 million Americans have Bipolar disorder. Nearly one-third of patients with major depressive disorder and nearly one-third of those with schizophrenia are defined as having treatment-resistant forms of these illnesses.
2. 82% of biopharmaceutical companies with research projects in areas including mental health expect substantial impacts on the pipeline. Many Americans grapple with Bipolar disorder, a mental health condition affecting approximately 4.4% of U.S. adults, translating to around 11.3 million individuals.
Global Bipolar Disorder Market Competitive Landscape
1. In May 2023, AbbVie’s acquisition of Allergan, the deal brought together two major pharmaceutical companies with stakes in the Global Bipolar Disorder treatment market. AbbVie’s portfolio includes established medications like lithium, while allergens had a presence through its central nervous system drugs. The combined entity is expected to leverage its broader portfolio and resources to drive further research and development in various therapeutic areas, potentially including Bipolar disorder treatments.
2.In 2023, there was a rise in the development and adoption of digital health solutions tailored for Bipolar disorder management. Mobile apps, wearable devices, and online platforms were designed to assist patients in tracking mood changes, medication adherence, and accessing support resources.
Global Bipolar Disorder Market Scope: Inquiry Before Buying
| Global Bipolar Disorder Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2023 | Forecast Period: | 2024-2030 |
| Historical Data: | 2018 to 2023 | Market Size in 2023: | US $ 5.5 Bn. |
| Forecast Period 2024 to 2030 CAGR: | 3.4% | Market Size in 2030: | US $ 6.95 Bn. |
| Segments Covered: | by Type | Global Bipolar Disorder I Disorder Global Bipolar Disorder II Disorder Cyclothymic Disorder |
|
| by Treatment Type | Mood Stabilizer Antipsychotics Antidepressant |
||
| by Mechanism of Action | Selective Serotonin Reuptake Inhibitor Serotonin Norepinephrine Reuptake Inhibitor Tricyclic Antidepressant Drug Benzodiazepines Beta Blockers |
||
Global Bipolar Disorder Market, by Region
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Global Bipolar Disorder Key Players
1. Johnson & Johnson (United States)
2. Pfizer Inc. (United States)
3. AstraZeneca plc (United Kingdom)
4. Eli Lilly and Company (United States)
5. Bristol Myers Squibb (United States)
6. Otsuka Pharmaceutical Co., Ltd. (Japan)
7. Allergan plc (Ireland)
8. AbbVie Inc. (United States)
9. GlaxoSmithKline plc (United Kingdom)
10. Novartis AG (Switzerland)
11. Lundbeck (Denmark)
12. Alkermes plc (Ireland)
13. Sumitomo Dainippon Pharma Co., Ltd. (Japan)
14. Takeda Pharmaceutical Company Limited (Japan)
15. Mitsubishi Tanabe Pharma Corporation (Japan)
16. Sunovion Pharmaceuticals Inc. (United States)
17. Boehringer Ingelheim International GmbH (Germany)
18. Janssen Pharmaceuticals, Inc. (United States)
19. Mylan N.V. (United States)
20. Recordati S.p.A. (Italy)
Frequently Asked Questions:
1] What is the projected market size & and growth rate of the Global Bipolar Disorder Market?
Ans. The Global Bipolar Disorder Market size was valued at USD 5.5 Billion in 2023 and the total Global Bipolar Disorder revenue is expected to grow at a CAGR of 3.4 % from 2024 to 2030, reaching nearly USD 6.95 Billion By 2030
2] What segments are covered in the Global Bipolar Disorder Market report?
Ans. The segments covered in the Global Bipolar Disorder Market report are based on Type, Treatment Type, and Mechanism of action.
3] Which region is expected to hold the highest share in the Global Bipolar Disorder Market?
Ans. The North American region is expected to hold the highest share of the Global Bipolar Disorder Market.
4] What are the growth drivers for the Global Bipolar Disorder Market?
Ans. The rising prevalence of mental health disorders, etc. is expected to be the major driver for the Global Bipolar Disorder Market.
5] What is the forecast period for the Global Bipolar Disorder Market?
Ans. The forecast period for the Global Bipolar Disorder Market is 2024-2030.